<DOC>
	<DOCNO>NCT02993913</DOCNO>
	<brief_summary>Phase I dose escalate trial . Primary objective study assess safety tolerability Simmiparib follow single multiple oral dos patient advance solid malignancy , determine maximum tolerance dose ( MTD ) dose limit toxicity ( DLT ) , pharmacokinetic profile . The Secondary objective observe preliminary antitumor effect Simmiparib .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Simmiparib Patients With Malignant Advanced Solid Tumor</brief_title>
	<detailed_description>This single-center , nonrandomized , open-label , dose-escalating study . The trial divide dose escalation expansion stage .</detailed_description>
	<criteria>1 . Patients confirm advanced solid tumor base pathology and/or cytology , consider unresponsive poorly responsive standard therapy , curative therapy ca n't tolerate standard therapy ; 2 . Patients must measurable disease accordance RECIST criterion v. 1.1 , least one lesion accurately measure CT MRI least one dimension ( long diameter≥10mm ; lymph node , short diameter≥15mm ) ; 3 . Age≥18 ≤75 year , men woman , history drug abuse alcohol ; 4 . Life expectancy≥ 3 month follow safety efficiency 5 . Received prior antitumor therapy least within past 4 week adjuvant antitumor regimen ( include steroid mediation ) 6 . Have recover to≤ common terminology criterion adverse event ( CTCAE ) 1 toxicity prior therapy 7 . Not participated clinical trial within 28 day ; 8 . Not receive treatment polyADP ribose polymerase ( PARP ) inhibitor ; 9 . No serious abnormal hematopoiesis function , adequate cardiac , pulmonic , hepatic renal function . Blood routine blood biochemical examination within 2 week enrollment : White blood cell ( WBC ) ≥4000/mm3 , Absolute neutrophil count ( ANC ) ≥1,500/mm3 , Platelets ≥100,000/mm3 , Coagulation function ≤ 1.5 time upper limit normal ( ULN ) , serum creatinine ≤ 1.5 time ULN , Total bilirubin ≤ 1.5 time ULN , Patients without liver metastasis , Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) ≤ 2.5 time ULN ; Patients liver metastasis , Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) /≤ 2.5 time ULN , NYHAclass≤Ⅱand Left ventricular ejection fraction ( LVEF ) &gt; 50 % ; 10 . Virology test : negative HbsAg , HCV , HIV syphilis 11 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 ; 12 . No history malignant tumor , except cervical carcinoma situ , basal skin cancer squamouscell carcinoma cure ; No serious illness conflict study significant heart disease psychosis ; 13 . Ability understand willingness sign write informed consent ; Obtaining consent operation 1 . Patients serious medical disease , include , severe cardiopathy , vascular disease , uncontrolled diabetes , uncontrolled hypertension , severe infection , psychosis , etc . ; 2 . Patients primary brain lesion metastases lesion ; 3 . Female patient pregnant , breast feeding unwilling contraception ; 4 . Patient receive receive investigational agent within 4 week prior treatment ; 5 . Patients , poor compliance , base opinion investigator , enrol study ; 6. recover grade 1 good adverse event relate previous therapy . 7 . Neurotoxicity observe previous antineoplastic therapy recover grade 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>